share_log

京新药业(002020.SZ):在美国的业务收入占公司整体业务收入的比例不大

Zhejiang Jingxin Pharmaceutical (002020.SZ): The revenue from the business in the USA accounts for a small proportion of the company's overall business revenue.

Gelonghui Finance ·  Mar 5 08:39

Gelonghui, March 5th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the revenue from its Business in the USA accounts for a small proportion of the company's overall Business revenue, and the additional tariffs imposed by the USA are expected to have no significant impact on the company's performance.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 245

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.